Video

Dr. Yao on the Milan Criteria in Liver Cancer

Author(s):

Francis Yao, MD, professor of Clinical Medicine and Surgery, medical director of the Liver Transplant Program at UCSF Medical Center, discusses the Milan criteria in liver cancer.

Francis Yao, MD, professor of Clinical Medicine and Surgery, medical director of the Liver Transplant Program at UCSF Medical Center, discusses the Milan criteria in liver cancer.

In the past, oncologists tended to transplant bulky tumors and would often see their patients' disease recur, says Yao. The Milan criteria, which were published in 1996, state that a patient with hepatocellular carcinoma (HCC) is selected for transplantation when he or she has a single lesion up to 5 centimeters, or 2 to 3 lesions up to 3 centimeters.

After the Milan criteria became a benchmark for the treatment of patients with HCC, some oncologists began to question whether the size or number of lesions could be expanded. Research suggested that patients with tumor sizes just beyond the Milan criteria may see very positive outcomes, according to Yao. UCSF proposed an updated set of criteria, which expanded the upper limit of the tumor size by 1.5 centimeters, or up to 3 nodules with the largest lesion up to 4.5 centimeters.

<<<

View more from the 2016 International Liver Cancer Association Annual Conference

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.